arrow
R

Ronald Hoffman

ichan school of medicine at mount sinai
H指数:64
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Type 1 interferon perturbates clonal competition by reshaping human blood development

I型干扰素通过重塑人类血液发育来扰乱克隆竞争

2026-09-150
OA
Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera

沙帕卢森用于真性红细胞增多症患者红细胞增多症的控制

Blood
IF23.1
2026-08-200
OA
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images

人工智能利用数字化骨髓活检图像区分伴血栓形成性血小板增多症的早期原发性骨髓纤维化与原发性血小板增多症

Leukemia
IF13.4
2026-02-200
OAAI
Loss of Function Mouse Models Reveal a Novel Regulatory Function for ULK1 in Myeloproliferative Neoplasms

功能缺失小鼠模型揭示ULK1在骨髓增殖性肿瘤中的新型调控功能

2025-07-230
PRE
TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

TP53改变使骨髓增殖性肿瘤患者发生白血病转化的风险增加,且较高分险分子突变患者的生存更差。

BLOOD
IF23.1
2024-11-050
PRE
A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

一项关于Nuvisertib(TP-3654)的1/2期研究,Nuvisertib是一种实验性选择性PIM1激酶抑制剂,与JAK抑制剂Ruxolitinib或Momelotinib联合用于骨髓纤维化患者。

BLOOD
IF23.1
2024-11-051
PRE